Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

RTTNews | 24 days ago
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln

(RTTNews) - Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.

The proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences' expertise in immune-mediated indications with Biogen's global development and commercial experience in rare diseases.

Biogen plans to leverage its existing global development and commercialization capabilities in rare disease and its strong scientific expertise in immunology to support the advancement of felzartamab and the HI-Bio pipeline.

The total potential deal value can go up to $1.8 billion, should the felzartamab programs achieve certain development milestones.

In addition to lead program felzartamab, the HI-Bio pipeline includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial.

Biogen seeks to retain expertise and talent from HI-Bio and establish a San Francisco Bay Area team focused on expanding our efforts in immune-mediated diseases.

Biogen expects to finance the acquisition with cash and may also draw on its revolving credit agreement. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals and is currently anticipated to close in the third quarter of 2024.

The acquisition of HI-Bio is not expected to impact Biogen's previously issued 2024 guidance.

read more
Biogen Q2 Results Top Estimates; Backs FY23 Outlook

Biogen Q2 Results Top Estimates; Backs FY23 Outlook

Biotechnology company Biogen, Inc. (BIIB) reported Tuesday that net income attributable to the company for the second quarter plunged to $591.6 million or $4.07 per share from $1.06 billion or $7.24 per share in the prior-year quarter.
RTTNews | 326 days ago
Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook

Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook

Biotechnology company Biogen Inc. (BIIB) reported Tuesday net income attributable to the company for the first quarter of $387.9 million or $2.67 per share, higher than $303.8 million or $2.06 per share in the prior-year quarter.
RTTNews | 417 days ago
Biogen Q4 Results Top Estimates

Biogen Q4 Results Top Estimates

Biotechnology company Biogen Inc. reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower expenses despite a 7 percent revenue growth. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also initiated adjusted earnings and revenue growth guidance for the full-year 2023, in line with estimates.
RTTNews | 486 days ago
Biogen Appoints Christopher Viehbacher As President And CEO

Biogen Appoints Christopher Viehbacher As President And CEO

Biotechnology company Biogen Inc. (BIIB) announced Thursday that its Board of Directors has appointed Christopher Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has led the company since 2017.
RTTNews | 583 days ago
Biogen Boosts FY22 Outlook As Q2 Results Top Estimates

Biogen Boosts FY22 Outlook As Q2 Results Top Estimates

While reporting financial results for the second quarter on Wednesday, Biogen Inc. (BIIB) raised its adjusted earnings and revenue guidance for the full-year 2022, based on better-than-expected topline performance and continued cost management. For fiscal 2022, the company continues to project adjusted earnings in the range of $15.25 to $16.75 per share on revenues between $9.90 billion and $10.1 billion.
RTTNews | 696 days ago